Hubert H Fernandez

Summary

Affiliation: University of Florida
Country: USA

Publications

  1. ncbi Rebound psychosis: effect of discontinuation of antipsychotics in Parkinson's disease
    Hubert H Fernandez
    Department of Neurology, University of Florida McKnight Brain Institute, Movement Disorders Program, Gainesville, Florida 32610, USA
    Mov Disord 20:104-5. 2005
  2. ncbi Botulinum toxin type B for gait freezing in Parkinson's disease
    Hubert H Fernandez
    Department of Clinical Neuroscience, Brown University School of Medicine, Providence, RI, USA
    Med Sci Monit 10:CR282-4. 2004
  3. ncbi Taking a closer look at sleep problems and psychosis in Parkinson's disease. Introduction
    Hubert H Fernandez
    Department of Neurology, University of Florida, Gainesville, FL 32610, USA
    CNS Spectr 13:4-5. 2008
  4. ncbi Diabetes mellitus among parkinsonian patients treated chronically with clozapine
    Hubert H Fernandez
    Department of Neurology, University of Florida, Gainesville, FL, USA
    Parkinsonism Relat Disord 10:439-41. 2004
  5. ncbi Depressive symptoms in Parkinson disease correlate with impaired global and specific cognitive performance
    Hubert H Fernandez
    Department of Neurology McKnight Brain Institute, University of Florida, Gainesville, USA
    J Geriatr Psychiatry Neurol 22:223-7. 2009
  6. ncbi Pharmacotherapy of dementia with Lewy bodies
    Hubert H Fernandez
    Division of Neurology, Memorial Hospital of Rhode Island, 111 Brewster Street, Pawtucket, RI 02860, USA
    Expert Opin Pharmacother 4:2027-37. 2003
  7. ncbi What we have learned about sleep disorders and psychosis after nearly two centuries of Parkinson's disease. Summary and conclusions
    Hubert H Fernandez
    Department of Neurology, University of Florida, Gainesville, FL, USA
    CNS Spectr 13:34-5. 2008
  8. ncbi Quetiapine improves visual hallucinations in Parkinson disease but not through normalization of sleep architecture: results from a double-blind clinical-polysomnography study
    Hubert H Fernandez
    Department of Neurology, College of Medicine, University of Florida, FL, USA
    Int J Neurosci 119:2196-205. 2009
  9. ncbi Istradefylline as monotherapy for Parkinson disease: results of the 6002-US-051 trial
    H H Fernandez
    Department of Neurology, University of Florida Movement Disorders Center, PO Box 100236, 100 South Newell Dr, L3 100, Gainesville, FL 32610 0236, USA
    Parkinsonism Relat Disord 16:16-20. 2010
  10. ncbi Scales to assess psychosis in Parkinson's disease: Critique and recommendations
    Hubert H Fernandez
    Department of Neurology, McKnight Brain Institute University of Florida, Gainesville, Florida 32611, USA
    Mov Disord 23:484-500. 2008

Research Grants

  1. Clinical Center for the Parkinson Disease Neuroprotection Clinical Trial
    Hubert Fernandez; Fiscal Year: 2006
  2. Clinical Center for the Parkinson Disease Neuroprotection Clinical Trial
    Hubert Fernandez; Fiscal Year: 2007

Detail Information

Publications94

  1. ncbi Rebound psychosis: effect of discontinuation of antipsychotics in Parkinson's disease
    Hubert H Fernandez
    Department of Neurology, University of Florida McKnight Brain Institute, Movement Disorders Program, Gainesville, Florida 32610, USA
    Mov Disord 20:104-5. 2005
    ..In 3 patients the "rebound psychosis" was worse than the original psychotic episode and required subsequent higher antipsychotic medication doses...
  2. ncbi Botulinum toxin type B for gait freezing in Parkinson's disease
    Hubert H Fernandez
    Department of Clinical Neuroscience, Brown University School of Medicine, Providence, RI, USA
    Med Sci Monit 10:CR282-4. 2004
    ..Freezing of Gait (FOG) can be a serious problem in Parkinson's disease (PD) and is usually refractory to medical treatment. Botulinum toxin (BTX) type A has been reported to relieve FOG in small open label studies...
  3. ncbi Taking a closer look at sleep problems and psychosis in Parkinson's disease. Introduction
    Hubert H Fernandez
    Department of Neurology, University of Florida, Gainesville, FL 32610, USA
    CNS Spectr 13:4-5. 2008
  4. ncbi Diabetes mellitus among parkinsonian patients treated chronically with clozapine
    Hubert H Fernandez
    Department of Neurology, University of Florida, Gainesville, FL, USA
    Parkinsonism Relat Disord 10:439-41. 2004
    ..3% for ages > or = 60 years). In this small study, parkinsonian patients on long-term, low dose clozapine were not at increased risk for developing DM. Larger controlled prospective studies are needed to confirm this...
  5. ncbi Depressive symptoms in Parkinson disease correlate with impaired global and specific cognitive performance
    Hubert H Fernandez
    Department of Neurology McKnight Brain Institute, University of Florida, Gainesville, USA
    J Geriatr Psychiatry Neurol 22:223-7. 2009
    ..Our study shows that while depressive symptoms correlated with global cognitive performance, naming, verbal memory, and language are the most susceptible cognitive domains affected with depressive symptoms...
  6. ncbi Pharmacotherapy of dementia with Lewy bodies
    Hubert H Fernandez
    Division of Neurology, Memorial Hospital of Rhode Island, 111 Brewster Street, Pawtucket, RI 02860, USA
    Expert Opin Pharmacother 4:2027-37. 2003
    ....
  7. ncbi What we have learned about sleep disorders and psychosis after nearly two centuries of Parkinson's disease. Summary and conclusions
    Hubert H Fernandez
    Department of Neurology, University of Florida, Gainesville, FL, USA
    CNS Spectr 13:34-5. 2008
  8. ncbi Quetiapine improves visual hallucinations in Parkinson disease but not through normalization of sleep architecture: results from a double-blind clinical-polysomnography study
    Hubert H Fernandez
    Department of Neurology, College of Medicine, University of Florida, FL, USA
    Int J Neurosci 119:2196-205. 2009
    ..Despite the small sample, this is the first double-blind trial to show quetiapine's efficacy over placebo in controlling VH in the PD population. However, normalization of sleep architecture was not supported as the mechanism...
  9. ncbi Istradefylline as monotherapy for Parkinson disease: results of the 6002-US-051 trial
    H H Fernandez
    Department of Neurology, University of Florida Movement Disorders Center, PO Box 100236, 100 South Newell Dr, L3 100, Gainesville, FL 32610 0236, USA
    Parkinsonism Relat Disord 16:16-20. 2010
    ..6002-US-051 was a 12-week, double-blind study evaluating the safety and efficacy of istradefylline, a selective A(2A) adenosine receptor antagonist, as monotherapy in patients with Parkinson's disease (PD)...
  10. ncbi Scales to assess psychosis in Parkinson's disease: Critique and recommendations
    Hubert H Fernandez
    Department of Neurology, McKnight Brain Institute University of Florida, Gainesville, Florida 32611, USA
    Mov Disord 23:484-500. 2008
    ..The CGIS is suggested as a secondary outcome scale to measure change and response to treatment over time...
  11. ncbi Monoamine oxidase-B inhibition in the treatment of Parkinson's disease
    Hubert H Fernandez
    Movement Disorders Center, University of Florida, McKnight Brain Institute, Gainesville, FL 32610, USA
    Pharmacotherapy 27:174S-185S. 2007
    ..A third agent with MAO-B inhibition properties, safinamide, is in phase III development. Although not yet approved, safinamide may offer the added advantage of combined MAO-B and dopamine reuptake inhibition...
  12. ncbi Drug-induced parkinsonism
    Frandy Susatia
    Hubert H Fernandez, MD McKnight Brain Institute, 100 South Newell Drive, Room L3 100, PO Box 100236, Gainesville, FL 32610 0236, USA
    Curr Treat Options Neurol 11:162-9. 2009
    ....
  13. ncbi Monamine oxidase inhibitors: current and emerging agents for Parkinson disease
    Hubert H Fernandez
    Movement Disorders Center, Department of Neurology, McKnight Brain Institute University of Florida, Gainesville, FL 32610, USA
    Clin Neuropharmacol 30:150-68. 2007
    ..Unlike selegiline, rasagiline is an aminoindan derivative with no amphetamine metabolites. A randomized clinical trial is underway to confirm preclinical and preliminary clinical data suggesting rasagiline has disease-modifying effects...
  14. ncbi Long-term outcome of clozapine use for psychosis in parkinsonian patients
    Hubert H Fernandez
    Department of Clinical Neurosciences, Brown Uniersity School of Medicine, Providence, Rhode Island, USA
    Mov Disord 19:831-3. 2004
    ..Our data are more consistent with recently published long-term outcome data suggesting an improvement in the prognosis of parkinsonian patients with psychosis with the use of atypical antipsychotic agents such as clozapine...
  15. ncbi Greater improvement in quality of life following unilateral deep brain stimulation surgery in the globus pallidus as compared to the subthalamic nucleus
    Laura B Zahodne
    Department of Clinical and Health Psychology, University of Florida, PO Box 100165, Gainesville, FL 32610 0165, USA
    J Neurol 256:1321-9. 2009
    ..Patients receiving GPi DBS reported greater improvements that cannot be explained by differential mood or motor effects; however, verbal fluency changes may have partially contributed to lesser QoL improvements amongst STN patients...
  16. ncbi Inappropriate crying and laughing in Parkinson disease and movement disorders
    Mustafa S Siddiqui
    Department of Neurology, Wake Forest University School of Medicine, Winston Salem, NC, USA
    World J Biol Psychiatry 10:234-40. 2009
    ..To examine in a pilot study inappropriate crying and laughing (also termed pseudobulbar affect (PBA)) and underlying mood disturbances in a large clinic based population of Parkinson's disease and movement disorder patients...
  17. ncbi Cognition and mood in Parkinson's disease in subthalamic nucleus versus globus pallidus interna deep brain stimulation: the COMPARE trial
    Michael S Okun
    Movement Disorders Center, University of Florida, McKnight Brain Institute, College of Medicine, Department of Neurology, Gainesville, FL 32611, USA
    Ann Neurol 65:586-95. 2009
    ..Our aim was to compare in a prospective blinded study the cognitive and mood effects of subthalamic nucleus (STN) vs. globus pallidus interna (GPi) deep brain stimulation (DBS) in Parkinson disease...
  18. ncbi Unilateral GPi-DBS as a treatment for levodopa-induced respiratory dyskinesia in Parkinson disease
    Genko Oyama
    Department of Neurology, University of Florida Movement Disorders Center, Gainesville, FL 32610, USA
    Neurologist 17:282-5. 2011
    ..Respiratory dyskinesia is a rare but disabling complication of levodopa therapy for Parkinson disease; however, its treatment has been limited to medication optimization...
  19. ncbi Reoperation for suboptimal outcomes after deep brain stimulation surgery
    Tina Marie Ellis
    Department of Neurology, Movement Disorders Center, University of Florida, McKnight Brain Institute, Gainesville, Florida, USA
    Neurosurgery 63:754-60; discussion 760-1. 2008
    ..The goal of the current study was to perform an unblinded retrospective chart review of DBS patients with unsatisfactory outcomes who presented for reoperation...
  20. ncbi Cognitive declines one year after unilateral deep brain stimulation surgery in Parkinson's disease: a controlled study using reliable change
    Laura B Zahodne
    Clinical and Health Psychology, University of Florida, Gainesville, FL 32610 0165, USA
    Clin Neuropsychol 23:385-405. 2009
    ..Finally, use of Reliable Change highlights the impact of individual variability and indicates that fluency declines likely reflect significant changes in a subset of patients who demonstrate a poorer surgical outcome overall...
  21. ncbi Pearls in patient selection for deep brain stimulation
    Ramon L Rodriguez
    Department of Neurology, University of Florida Movement Disorders Center, McKnight Brain Institute, Gainesville, Florida, USA
    Neurologist 13:253-60. 2007
    ..General neurologists and even general practitioners may be called upon to screen potential candidates for DBS. The patient selection process plays an important role in this procedure...
  22. ncbi A case-based review of troubleshooting deep brain stimulator issues in movement and neuropsychiatric disorders
    Michael S Okun
    Department of Neurology and Neurosurgery, Movement Disorders Center, McKnight Brain Institute, Gainesville, FL 32610, USA
    Parkinsonism Relat Disord 14:532-8. 2008
    ..To review the spectrum of problems that can occur in the DBS patient and to suggest potential troubleshooting tips for identification and management of DBS related issues...
  23. ncbi Is rhinorrhea an under-recognized intrinsic symptom of Parkinson disease? A prospective pilot study
    Laura Sedig
    College of Medicine, University of Florida, Gainesville, Florida 32610, USA
    Int J Neurosci 120:258-60. 2010
    ..The purpose of this study is to compare the prevalence of idiopathic rhinorrhea in PD patients versus controls, to determine the correlation between rhinorrhea and anosmia, and the factors associated with rhinorrhea...
  24. ncbi Binge eating in Parkinson's disease: prevalence, correlates and the contribution of deep brain stimulation
    Laura B Zahodne
    Dept of Clinical and Health Psychology, University of Florida in Gainesville, FL, USA
    J Neuropsychiatry Clin Neurosci 23:56-62. 2011
    ..More overeaters had a history of subthalamic deep brain stimulation (DBS; 44% versus 14%). History of DBS was the only independent predictor of overeating...
  25. ncbi The impact of and the factors associated with drooling in Parkinson's disease
    Joshua Leibner
    College of Medicine, University of Florida, Gainesville, FL 32610, USA
    Parkinsonism Relat Disord 16:475-7. 2010
    ..Experiencing hallucinations was the only factor that correlated with being a drooler and it may be confounded by medications...
  26. ncbi The relationship between anosmia, constipation, and orthostasis and Parkinson's disease duration: results of a pilot study
    Amit L Ramjit
    College of Medicine, University of Florida Gainesville, FL32608, USA
    Int J Neurosci 120:67-70. 2010
    ..038 and .04 respectively). Our study suggests that increasing levels of dopaminergic therapy inhibits reflexive tachycardia. Furthermore, our study suggests that anosmia and constipation progress with the primary disease process...
  27. ncbi Factors related to extended hospital stays following deep brain stimulation for Parkinson's disease
    Ania Mikos
    Department of Clinical and Health Psychology, University of Florida, Movement Disorders Center, McKnight Brain Institute, Gainesville FL, USA
    Parkinsonism Relat Disord 16:324-8. 2010
    ..This study examined potential factors that might have corresponded to increased post-operative stays following unilateral DBS surgery...
  28. ncbi Long-term outcome of quetiapine use for psychosis among Parkinsonian patients
    Hubert H Fernandez
    Department of Clinical Neurosciences, Brown University School of Medicine, Providence, Rhode Island, USA
    Mov Disord 18:510-4. 2003
    ..6; 95% CI = 1.4-92.9). Also, patients who developed motor worsening while on quetiapine tended to be more demented (P = 0.07)...
  29. ncbi Steady or not following thalamic deep brain stimulation for essential tremor
    Nelson Hwynn
    Department of Neurology, McKnight Brain Institute, University of Florida, 100 S Newell Drive, rm L3 100, Gainesville, FL, 32610, USA
    J Neurol 258:1643-8. 2011
    ..The larger percentage of difficulties observed in unilateral versus bilateral cases likely reflected the bias not to proceed to second-sided surgery if gait/balance problems were encountered...
  30. ncbi Weight changes in subthalamic nucleus vs globus pallidus internus deep brain stimulation: results from the COMPARE Parkinson disease deep brain stimulation cohort
    Maren C Locke
    Department of Neurology, University of Florida Movement Disorders Center McKnight Brain Institute, Gainesville, Florida 32611, USA
    Neurosurgery 68:1233-7; discussion 1237-8. 2011
    ..Parkinson's patients, on average, gain weight after deep brain stimulation (DBS)...
  31. ncbi Deep brain stimulation and the role of the neuropsychologist
    Michael S Okun
    Department of Neurology, Movement Disorders Center, University of Florida, Gainesville, FL 32610, USA
    Clin Neuropsychol 21:162-89. 2007
    ..Additionally, this article will review all aspects of the DBS procedure that can result in mood, cognitive, and behavioral effects and what role(s) the neuropsychologist should play in screening and follow-up...
  32. ncbi Mood and energy determinants of quality of life in dystonia
    Anne Soeder
    Department of Neurology, University of Florida, Gainesville, FL, USA
    J Neurol 256:996-1001. 2009
    ..Further studies will be needed to determine the effect of treatment on these associations and whether disturbances in energy are related to sleep disturbances or to primary fatigue issues...
  33. ncbi Clinical cases where lesion therapy was chosen over deep brain stimulation
    Amanda K Hooper
    University of Florida, Movement Disorders Center, Gainesville, FL 32601, USA
    Stereotact Funct Neurosurg 86:147-52. 2008
    ..Lesion therapy represents a viable alternative and has several important advantages, including a decreased need for access to specialists and clinical follow-up, improved affordability, and a lower infection risk...
  34. ncbi Quetiapine for psychosis in Parkinson's disease versus dementia with Lewy bodies
    Hubert H Fernandez
    Department of Clinical Neurosciences, Brown University School of Medicine, Providence, RI, USA
    J Clin Psychiatry 63:513-5. 2002
    ..Most clinicians perceive psychosis in dementia with Lewy bodies (DLB) as more difficult to treat than Parkinson's disease, yet there are no reports comparing the antipsychotic response between the 2 disorders...
  35. ncbi Relationship between higher rates of adverse events in deep brain stimulation using standardized prospective recording and patient outcomes
    Adam P Burdick
    Department of Neurosurgery, University of Florida, Gainesville, Florida 32610, USA
    Neurosurg Focus 29:E4. 2010
    ..In this paper the authors disclose the standardized and prospectively recorded AE data from their institution, correlated with clinical outcome and quality of life (QOL) measures...
  36. ncbi Community and long-term care management of Parkinson's disease in the elderly: focus on monoamine oxidase type B inhibitors
    Jack J Chen
    Movement Disorders Center, Schools of Medicine and Pharmacy, Loma Linda University, Loma Linda, California 92350, USA
    Drugs Aging 24:663-80. 2007
    ..The favourable safety profile of rasagiline in the elderly and its once-daily formulation may maximise drug adherence and improve outcomes...
  37. ncbi Differential response of dystonia and parkinsonism following globus pallidus internus deep brain stimulation in X-linked dystonia-parkinsonism (Lubag)
    Genko Oyama
    Department of Neurology, University of Florida College of Medicine Shands Hospital, Movement Disorders Center, McKnight Brain Institute, Gainesville, FL 32610, USA
    Stereotact Funct Neurosurg 88:329-33. 2010
    ..X-linked dystonia-parkinsonism (XDP; DYT3; Lubag) is an adult-onset hereditary progressive dystonia/parkinsonism which is typically minimally responsive to pharmacological treatment...
  38. ncbi Examination of the Lille Apathy Rating Scale in Parkinson disease
    Laura B Zahodne
    Department of Clinical and Health Psychology, University of Florida, Gainesville, Florida 32610 0165, USA
    Mov Disord 24:677-83. 2009
    ..Although the present study does not compare the LARS to a diagnostic gold standard or promote its utility for diagnosing apathy, it provides further support for the LARS as a promising instrument to examine apathy in PD...
  39. ncbi A closer look at unilateral versus bilateral deep brain stimulation: results of the National Institutes of Health COMPARE cohort
    Houtan A Taba
    Department of Neurology, University of Forlida Movement Disorders Center, College of Medicine, University of Florida, Gainesville, FL 32611, USA
    J Neurosurg 113:1224-9. 2010
    ..In this paper, the authors' aim was to examine reasons underpinning decisions to undergo, or alternatively forgo, a second-sided deep brain stimulation (DBS) implantation in patients with Parkinson disease (PD)...
  40. ncbi Nonmotor complications of Parkinson disease
    Hubert H Fernandez
    Movement Disorders Program, Center for Neurological Restoration, Cleveland Clinic, Cleveland, OH 44195, USA
    Cleve Clin J Med 79:S14-8. 2012
    ..Thus, a balance must be struck between controlling nonmotor manifestations and motor features of the disease...
  41. ncbi Unilateral deep brain stimulation surgery in Parkinson's disease improves ipsilateral symptoms regardless of laterality
    Kamal Shemisa
    Department of Neurosurgery, College of Medicine, University of Florida, Gainesville, FL, USA
    Parkinsonism Relat Disord 17:745-8. 2011
    ..We hypothesised that among Parkinson right-handers, unilateral left DBS would provide greater ipsilateral motor improvement compared with the ipsilateral motor improvement experienced on the right side...
  42. ncbi Effects of dopaminergic medication on objective tasks of deftness, bradykinesia and force control
    Kim C Stewart
    Department of Applied Physiology and Kinesiology, University of Florida, Florida Gym Room 151, Gainesville, FL 32611, USA
    J Neurol 256:2030-5. 2009
    ....
  43. ncbi Abnormal affective startle modulation in individuals with psychogenic [corrected] movement disorder
    Paul J Seignourel
    Department of Clinical and Health Psychology, University of Florida, Gainesville, Florida, USA
    Mov Disord 22:1265-71. 2007
    ..Abnormal affective startle modulation may be used to help distinguish between malingering and PMD. Future studies using larger samples are needed to better understand the role of emotions in conversion disorder...
  44. ncbi The "chair test" to aid in the diagnosis of psychogenic gait disorders
    Michael S Okun
    Department of Neurology, University of Florida, McKnight Brain Institute, Gainesville, Florida 32610, USA
    Neurologist 13:87-91. 2007
    ..To evaluate the chair test for diagnosis of psychogenic gait disorders...
  45. ncbi How cautious should we be when assessing apathy with the Unified Parkinson's Disease Rating Scale?
    Lindsey Kirsch-Darrow
    Department of Clinical and Health Psychology, College of Public Health and Health Professions, University of Florida, Gainesville, Florida 32610 0165, USA
    Mov Disord 24:684-8. 2009
    ..g., 3, 4) continues to increase specificity at the expense of dramatically reducing sensitivity. These findings suggest the use of caution when screening for apathy with item 4 due to its poor sensitivity in relation to the AS...
  46. ncbi Laterality, region, and type of motor dysfunction correlate with cognitive impairment in Parkinson's disease
    Lindsy N Williams
    Department of Neurology, University of Florida College of Medicine, Gainesville, Florida 32610, USA
    Mov Disord 22:141-5. 2007
    ..22, t(105) = -1.95, P = 0.054. We therefore found that right-sided symptoms (for laterality), axial symptoms (for region), and bradykinesia (for type of symptoms) were the best predictors of cognitive function...
  47. ncbi The Frequency of Nonmotor Symptoms among Advanced Parkinson Patients May Depend on Instrument Used for Assessment
    Nelson Hwynn
    University of Florida Center for Movement Disorders and Neurorestoration, University of Florida, Gainesville, FL 32607, USA
    Parkinsons Dis 2011:290195. 2011
    ..Conclusion The frequency of NMS among advanced PD patients and correlation between patients and caregivers varied with the instrument used. The overall correlation between patient and caregiver was greater with NMS-Q than NMS-S...
  48. ncbi Atypical antipsychotics in Parkinson-sensitive populations
    Joseph H Friedman
    Department of Clinical Neurosciences, Brown University School of Medicine, Providence, Rhode Island, USA
    J Geriatr Psychiatry Neurol 15:156-70. 2002
    ..Suggestions are made for future research to improve the interpretability of these studies...
  49. ncbi Effect of Deep Brain Stimulation on Parkinson's Nonmotor Symptoms following Unilateral DBS: A Pilot Study
    Nelson Hwynn
    Center for Movement Disorders and Neurorestoration, College of Medicine, University of Florida, Gainesville, FL 32610, USA
    Parkinsons Dis 2011:507416. 2011
    ..Future studies are needed to confirm these findings and determine their clinical significance as well as to examine the strengths/weaknesses of each questionnaire/scale...
  50. ncbi Venous air embolism in deep brain stimulation
    Amanda K Hooper
    University of Florida Movement Disorders Center, Gainesville, Fla 32601, USA
    Stereotact Funct Neurosurg 87:25-30. 2009
    ..Although VAEs have been described in many types of neurosurgical procedures, their incidence during DBS surgery is unknown...
  51. ncbi Side onset influences motor impairments in Parkinson disease
    Kim C Stewart
    Department of Applied Physiology and Kinesiology, University of Florida, Gainesville, FL 32611, USA
    Parkinsonism Relat Disord 15:781-3. 2009
    ..The low numbers of left-handed subjects and the significant percentage of left-handers with a dominant left hemisphere prevented a clear interpretation of our findings in left-handed subjects...
  52. ncbi Lessons learned in deep brain stimulation for movement and neuropsychiatric disorders
    Frank M Skidmore
    Department of Neurology, McKnight Brain Institute, University of Florida College of Medicine in Gainesville, 32610, USA
    CNS Spectr 11:521-36. 2006
    ..Also discussed are the emerging targets, what is known about the cognitive sequelae of DBS, and what has been learned about the complications and therapeutic failures...
  53. ncbi Tests of dorsolateral frontal function correlate with objective tests of postural stability in early to moderate stage Parkinson's disease
    Joe R Nocera
    Brain Rehabilitation Research Center, Malcom Randall VAMC, Gainesville, FL, USA
    Parkinsonism Relat Disord 16:590-4. 2010
    ..Greater understanding of the relationship between motor and cognitive processes in Parkinson's disease will be critical for understanding the disease process and its potential therapeutic possibilities...
  54. ncbi Rationale for current therapies in Parkinson's disease
    Janet Romrell
    University of Florida, Department of Neurology, McKnight Brain Institute, PO Box 100236, Gainesville, FL 32610, USA
    Expert Opin Pharmacother 4:1747-61. 2003
    ..Even though there have been great advances in the medical options for symptomatic management of PD, there are still many unmet needs for this patient population...
  55. ncbi Deep brain stimulation of the internal segment of the globus pallidus in delayed runaway dyskinesia
    John Graff-Radford
    Department of Neurology, University of Florida Movement Disorders Center, University of Florida, Gainesville, FL, USA
    Arch Neurol 63:1181-4. 2006
    ..CONCLUSION: This case highlights the delayed development of runaway dyskinesia after a period without medication as an important potential long-term adverse effect of embryonic cell transplantation in patients with Parkinson disease...
  56. ncbi Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group
    Bernard Ravina
    Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, NY 14620, USA
    Mov Disord 22:1061-8. 2007
    ..These criteria require validation and may be refined, but form a starting point for studies of the epidemiology and pathophysiology of PDPsy, and are a potential indication for therapy development...
  57. ncbi The four As associated with pathological Parkinson disease gamblers: anxiety, anger, age, and agonists
    Michael A Shapiro
    Department of Neurology, Movement Disorders Center, McKnight Brain Institute, University of Florida College of Medicine, Gainesville, FL, USA
    Neuropsychiatr Dis Treat 3:161-7. 2007
    ..Thus in this cohort, we have uncovered the several characteristics of the most likely PD compulsive gambler, namely: (young) age, "angry", "anxious", and using a (dopamine) agonist...
  58. ncbi Awareness of expressivity deficits in non-demented Parkinson disease
    Ania E Mikos
    Department of Clinical and Health Psychology, University of Florida, Gainesville, FL 32601, USA
    Clin Neuropsychol 23:805-17. 2009
    ..These findings highlight the view that diminished emotional expressivity in PD should not be mistaken for decreased subjective emotional experience...
  59. ncbi Testosterone therapy in men with Parkinson disease: results of the TEST-PD Study
    Michael S Okun
    Department of Neurology, University of Florida Movement Disorders Center, McKnight Brain Institute, Gainesville, FL 32610, USA
    Arch Neurol 63:729-35. 2006
    ..Previously, we reported that testosterone deficiency is more common in patients with PD compared with age-matched control subjects, and we also reported in 2 small open-label studies that some nonmotor symptoms responded favorably to TT...
  60. ncbi Distribution of motor impairment influences quality of life in Parkinson's disease
    Kim C Stewart
    Department of Applied Physiology and Kinesiology, University of Florida, Gainesville, Florida 32611, USA
    Mov Disord 23:1466-8. 2008
    ..Patients with greater UE and LE motor impairments had lower QoL scores. However, LE impairments had a greater influence than UE impairments across all QoL measures...
  61. ncbi Hypersexuality and paraphilia induced by selegiline in Parkinson's disease: report of 2 cases
    Michael A Shapiro
    Department of Neurology, McKnight Brain Institute, University of Florida College of Medicine, P.O. Box 100236, Gainesville, FL 32610, USA
    Parkinsonism Relat Disord 12:392-5. 2006
    ..Social repercussions may prohibit patients and/or their families from volunteering such information...
  62. ncbi Course, prognosis, and management of psychosis in Parkinson's disease: are current treatments really effective?
    Laura B Zahodne
    Department of Clinical and Health Psychology, University of Florida, Gainesville, FL, USA
    CNS Spectr 13:26-33. 2008
    ..An emerging treatment option is acetylcholinesterase inhibitors. This article reviews what is currently known about the course, prognosis, and treatment strategies in Parkinson's disease psychosis...
  63. ncbi Dual electrode thalamic deep brain stimulation for the treatment of posttraumatic and multiple sclerosis tremor
    Kelly D Foote
    Department of Neurology and Neurosurgery, University of Florida, Gainesville, Florida 32610, USA
    Neurosurgery 58:ONS-280-5; discussion ONS-285-6. 2006
    ..Two electrodes may be better than one for the treatment of certain disorders; however, more study will be required to confirm this hypothesis...
  64. ncbi Neuropsychological profile of a Filipino gentleman with X-linked dystonia-parkinsonism: a case report of Lubag disease
    Laura L S Howe
    Clinical and Health Psychology, McKnight Brain Institute, University of Florida, Gainesville, FL, USA
    Clin Neuropsychol 23:100-17. 2009
    ..He was evaluated for suitability for deep brain stimulation surgery. Neuropsychological findings demonstrated diffuse impairment involving memory, visuospatial, language, and executive functioning...
  65. ncbi Identifying candidates for deep brain stimulation in Parkinson's disease: the role of the primary care physician
    Michael S Okun
    Department of Neurology, University of Florida Movement Disorders Center, McKnight Brain Institute, Gainesville, USA
    Geriatrics 62:18-24. 2007
    ..Potential candidates who score well on this questionnaire can be referred for presurgical multidisciplinary evaluation at an experienced DBS implanting center...
  66. ncbi Aripiprazole for drug-induced psychosis in Parkinson disease: preliminary experience
    Hubert H Fernandez
    Department of Neurology, University of Florida College of Medicine, Gainesville, FL 32610
    Clin Neuropharmacol 27:4-5. 2004
    ..Our preliminary experience with aripiprazole is mixed but not very encouraging. Controlled studies are needed to evaluate aripiprazole in parkinsonian patients...
  67. ncbi Parkinsonism in a nursing home: underrecognition
    Joseph H Friedman
    Division of Neurology, Memorial Hospital of Rhode Island, 111 Brewster St, Pawtucket, RI 02860, USA
    J Geriatr Psychiatry Neurol 17:39-41. 2004
    ..02). Only 1 patient with drug-induced parkinsonism and 3 residents with previously diagnosed Parkinson's disease had chart notes indicating that parkinsonism had been recognized...
  68. ncbi Treatment of psychosis in Parkinson's disease: safety considerations
    Hubert H Fernandez
    Department of Clinical Neurosciences, Brown University School of Medicine, Providence, Rhode Island, USA
    Drug Saf 26:643-59. 2003
    ..Electroconvulsive treatment is generally reserved for the patient with psychotic depression who is unable to tolerate any pharmacological therapy...
  69. ncbi Deep brain stimulation of the GPi treats restless legs syndrome associated with dystonia
    Michael S Okun
    Departments of Neurology, University of Florida, McKnight Brain Institute, Gainesville, Florida 32610, USA
    Mov Disord 20:500-1. 2005
    ....
  70. ncbi Management of referred deep brain stimulation failures: a retrospective analysis from 2 movement disorders centers
    Michael S Okun
    Department of Neurology, University of Florida, Movement Disorders Center, McKnight Brain Institute, Gainesville, FL 32610, USA
    Arch Neurol 62:1250-5. 2005
    ..An attempt is made herein to evaluate the reasons for DBS failure in a series of such patients and to make recommendations to improve overall DBS outcomes...
  71. ncbi Paraneoplastic chorea with leukoencephalopathy presenting with obsessive-compulsive and behavioral disorder
    Susanne Muehlschlegel
    Department of Neurology, Movement Disorders Center, University of Florida College of Medicine, Gainesville, Florida, USA
    Mov Disord 20:1523-7. 2005
    ..We report on a case of CV2 paraneoplastic syndrome with obsessive-compulsive behavior preceding the motor manifestations of chorea with associated leukoencephalopathy on MRI. The literature on paraneoplastic chorea is reviewed...
  72. ncbi DBS candidates that fall short on a levodopa challenge test: alternative and important indications
    Takashi Morishita
    Department of Neurosurgery, College of Medicine Shands Hospital
    Neurologist 17:263-8. 2011
    ..The aim of this study was to examine the outcomes of DBS in a subset of patients who failed to reach the 30% motor improvement threshold...
  73. ncbi Apomorphine therapy in Parkinson's disease: a review
    Ihtsham Ul Haq
    Movement Disorders Program, University of Florida, Department of Neurology McKnight Brain Institute, 100 S Newell Drive, PO Box 100236, Gainesville, Florida 32610 0236, USA
    Expert Opin Pharmacother 8:2799-809. 2007
    ..In this review, the authors discuss the history, pharmacology, efficacy, safety and proper administration of apomorphine for treating 'off' states in Parkinson's disease, with a focus on intermittent subcutaneous administration...
  74. ncbi Hemiballismus from a parietal stroke in a Parkinson patient
    Motasem Al-Yacoub
    Department of Clinical Neurosciences, Brown University School of Medicine, Providence, RI, USA
    Mov Disord 19:986-8. 2004
    ..This suggests that HB itself, whether from a lesion in the subthalamic nucleus or elsewhere, is not what improves motor function in PD; instead, the physiological function of the damaged structure is the determining factor...
  75. ncbi When should levodopa therapy be initiated in patients with Parkinson's disease?
    Irene A C Halkias
    Department of Neurology, University of Florida, Gainesville, Florida 32608, USA
    Drugs Aging 24:261-73. 2007
    ..However, because of levodopa's superior efficacy, when a rapid and sustained symptomatic improvement is required because of significant motor disability, levodopa may be used as the first-line agent regardless of age...
  76. ncbi The effect of deep brain stimulation surgery on repetitive behavior in Parkinson patients: A case series
    Mary F Wood
    Department of Neurology, University of Florida, Gainesville, FL, USA
    Neurocase 16:31-6. 2010
    ..In this series, DBS surgery seemed to have no acute effect on repetitive behavior. It is difficult to ascertain whether DBS improves repetitive behavior chronically because of confounding factors in our three cases...
  77. ncbi Combating psychosis in Parkinson's disease patients: the use of antipsychotic drugs
    Kelvin L Chou
    Department of Clinical Neurosciences, Brown Medical School, Providence, Rhode Island, USA
    Expert Opin Investig Drugs 15:339-49. 2006
    ....
  78. ncbi Role of deep brain stimulation targeted to the pedunculopontine nucleus in Parkinson's disease
    Christopher Kenney
    Expert Rev Neurother 7:585-9. 2007
  79. ncbi Psychosis in Parkinson's disease
    Dylan P Wint
    Department of Psychiatry, McKnight Brain Institute/University of Florida, Gainesville 32610, USA
    J Geriatr Psychiatry Neurol 17:127-36. 2004
    ..An emerging treatment option is the use of acetylcholinesterase inhibitors. This article reviews what is known about the epidemiology, risk factors, pathophysiology, and treatment of PD-related psychosis...
  80. ncbi Cognitive and behavioral features discriminate between Alzheimer's and Parkinson's disease
    Deborah A Cahn-Weiner
    Memorial Hospital of Rhode Island and Brown Medical School, Pawtucket 02860, USA
    Neuropsychiatry Neuropsychol Behav Neurol 15:79-87. 2002
    ..To compare the cognitive and behavioral profiles of Alzheimer's disease (AD) and cognitively impaired patients with Parkinson's disease (PD) and to determine the individual measures that best discriminate the two patient groups...
  81. ncbi Punding as a complication of brain stem stroke?: report of a case
    Frederic N Nguyen
    Department of Neurology, University of Florida College of Medicine, Gainesville, FL 32610, USA
    Stroke 38:1390-2. 2007
    ..We describe a non-Parkinson disease case of nonpharmacologically induced punding as a complication of a brain stem cardiovascular accident...
  82. ncbi Efficacy and safety of purified botulinum toxin type A (Dysport) for the treatment of benign essential blepharospasm: a randomized, placebo-controlled, phase II trial
    Daniel Truong
    The Parkinson s and Movement Disorder Institute, Orange Coast Memorial Medical Center, 9940 Talbert Ave 204, Fountain Valley, CA 92708, USA
    Parkinsonism Relat Disord 14:407-14. 2008
    ..The best balance of sustained efficacy and favorable safety profile was provided by 80 units of Dysport/eye in this study...
  83. ncbi 18F-Dopa vs dopamine transporter ligands in positron emission tomographic and single-photon emission computed tomographic scans for Parkinson disease
    Hubert H Fernandez
    Arch Neurol 59:1973; author reply 1973-4. 2002
  84. ncbi Unrecognized parkinsonism in acute care medical patients receiving neurological consultations
    Joseph H Friedman
    J Gerontol A Biol Sci Med Sci 58:94-5. 2003
  85. ncbi Classification and treatment of tardive syndromes
    Hubert H Fernandez
    Department of Clinical Neurosciences, Brown University School of Medicine, Providence, Rhode Island, USA
    Neurologist 9:16-27. 2003
    ..Tardive syndromes are a group of delayed-onset abnormal involuntary movement disorders induced by a dopamine receptor blocking agent. There are several phenomenologically distinct types of TS...
  86. ncbi Avoiding deep brain stimulation failures in Tourette syndrome
    Michael S Okun
    J Neurol Neurosurg Psychiatry 79:111-2. 2008
  87. ncbi Comprehensive screening of a North American Parkinson's disease cohort for LRRK2 mutation
    Janel Johnson
    Laboratory of Neurogenetics, National Institute on Aging, Porter Neuroscience Research Center, National Institutes of Health, Bethesda, MD 20892, USA
    Neurodegener Dis 4:386-91. 2007
    ..Recently, mutations in LRRK2 encoding the protein dardarin have been linked to an autosomal dominant form of parkinsonism...
  88. ncbi Common neurologic disorders affecting the foot
    Rochelle J Woods
    Department of Clinical Neurosciences, Brown Medical School, Providence, RI, USA
    J Am Podiatr Med Assoc 94:104-17. 2004
    ..This article reviews the pathophysiology, clinical manifestations, and management of the common neurologic disorders affecting the foot...
  89. ncbi Genome-wide genotyping in Parkinson's disease and neurologically normal controls: first stage analysis and public release of data
    Hon Chung Fung
    Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD 20892, USA
    Lancet Neurol 5:911-6. 2006
    ....
  90. ncbi REM behavior disorder and excessive daytime somnolence in Machado-Joseph disease (SCA-3)
    Joseph H Friedman
    Department of Clinical Neurosciences, Brown University School of Medicine, Providence, Rhode Island 02860, USA
    Mov Disord 18:1520-2. 2003
    ..Our results support the previous observation that RBD-like behaviors are significantly increased in SCA-3...
  91. ncbi Analysis of the PINK1 gene in a large cohort of cases with Parkinson disease
    Ekaterina Rogaeva
    Centre for Research in Neurodegenerative Diseases and Division of Neurology, Department of Medicine, Toronto Western Hospital, University of Toronto, Ontario, Canada
    Arch Neurol 61:1898-904. 2004
    ..Mutations in the PTEN-induced kinase (PINK1) gene located within the PARK6 locus on chromosome 1p35-p36 have recently been identified in patients with recessive early-onset Parkinson disease...
  92. ncbi Tardive dyskinesia
    Karla Soares Weiser
    Enhance Reviews, Kfar Saba, Israel
    Semin Neurol 27:159-69. 2007
    ..None of the trials pooled on these reviews found a definitive therapy for TD. Clinicians faced with conditions such as TD should carefully weigh the risks and benefits involved with any given intervention...
  93. ncbi The human prion gene M129V polymorphism is not associated with idiopathic Parkinson's disease in three distinct populations
    Sonja W Scholz
    Molecular Genetics Unit, National Institute on Aging, National Institutes of Health, Building 35, Room 1A 1012, Bethesda, MD 20892, USA
    Neurosci Lett 395:227-9. 2006
    ..No association between genotypes in codon 129 and IPD was detected in three distinct populations, suggesting that this PRNP polymorphism has no direct influence on the susceptibility to IPD...
  94. ncbi Predictors of mortality among nursing home residents with a diagnosis of Parkinson's disease
    Hubert H Fernandez
    Department of Clinical Neurosciences, Brown University School of Medicine, Providence, RI, USA
    Med Sci Monit 8:CR241-6. 2002
    ..Minority groups have a reduced risk of death relative to white PD nursing home residents...

Research Grants3

  1. Clinical Center for the Parkinson Disease Neuroprotection Clinical Trial
    Hubert Fernandez; Fiscal Year: 2006
    ..abstract_text> ..
  2. Clinical Center for the Parkinson Disease Neuroprotection Clinical Trial
    Hubert Fernandez; Fiscal Year: 2007
    ..abstract_text> ..